Glad

Davanrik was developed to treat depression. However it was later found forbid that it also affected the hunger of the person and could be put on as a do medicates for obesity long-sufferings. Davanrik was currently in the pre-clinical development stage when it was offered to Merck to licence it. Since research laboratory was a subaltern company could not afford to get it through with(predicate) the FDA citation process. LAB offered to give the rights to Merck if pay it an initial lean rundown honorarium on each stage and study the drug through the entire FDA approval stage, manufacture the drug, foodstuff the drug and pay a royalty on entirely gross revenue to LAB. Clinical Approval Stages In build 1, the drug would be administered to 20-80 healthy volunteers to test for safety. The stage would get a line 2 years. If Merck opinionated to go ahead with the first descriptor investment, it would cost $30 jillion including an initial $5 one million million fee to LAB for licensing the drug. Probability of success of bod 1 is 60%.

In Phase 2, a larger number (100-300) of patient volunteers argon tested to determine if the drug is effective or not. Does the recitation of drug have any side cause on patients. It was estimated that there is only 10% prospect that Phase 2 would show that Davanrik would be effective for depression only, 15% opportunity for weight loss only, and a 5% probability for both(prenominal) depression and weight loss. This phase would also require 2 years and would cost $40 million including a $2.5 million licensing milestone payment to LAB.If you want to get a enough essay, order it on o! ur website: OrderCustomPaper.com

If you want to get a full essay, visit our page: write my paper